Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814407 | 1.00 | FABP5 (0.39) | FABP5FABP7MDM4TP53KIF11 | |
| SCHEMBL2817453 | 0.94 | KIF11 (0.45) | FABP5FABP7MDM4TP53KIF11 | |
| SCHEMBL2817454 | 0.94 | KIF11 (0.45) | FABP5FABP7MDM4TP53KIF11 | |
| SCHEMBL23722969 | 0.90 | KIF11 (0.40) | FABP5FABP7MDM4TP53KIF11 | |
| SCHEMBL31714132 | 0.90 | KIF11 (0.40) | FABP5FABP7MDM4TP53KIF11 | |
| SCHEMBL29511437 | 0.90 | KIF11 (0.40) | FABP5FABP7MDM4TP53KIF11 | |
| SCHEMBL29611191 | 0.90 | KIF11 (0.40) | FABP5FABP7MDM4TP53KIF11 | |
| SCHEMBL4409339 | 0.90 | KIF11 (0.40) | FABP5FABP7MDM4TP53KIF11 | |
| SCHEMBL29399007 | 0.86 | FABP5 (0.40) | FABP5FABP7MDM4TP53KMT2A | |
| SCHEMBL120598 | 0.86 | FABP5 (0.40) | FABP5FABP7MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659364-B2 | N-methyl-homocysteines and their use as well as process for their production | CIS BIO INTERNATIONAL (FR) | 2010-02-09 | — | — | US | disclosed |
| EP-1444194-B1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | CIS BIO INT (FR) | 2009-12-09 | — | — | EP | disclosed |
| EP-1444194-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | SCHERING AG (DE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003042163-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | BHMT, BHMT2, AHCY | FABP5 2008/4885FABP7 649/4885MDM4 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.